Daily Mosnodenvir as Dengue Prophylaxis in a Controlled Human Infection Model
In a controlled human infection model, a high daily dose of oral mosnodenvir led to a significantly lower DENV-3 RNA load than placebo. Mosnodenvir did not result in any serious adverse events. (Funded by the National Institute of Allergy and Infectious Diseases and Johnson & Johnson; ClinicalTrials.gov number, NCT05048875.).
Authors
- Beulah P. Sabundayo
- Liesbeth Van Wesenbeeck (ORCID: https://orcid.org/0000-0002-1760-9854)
- Guillermo Herrera‐Taracena
- Yannick Vandendijck (ORCID: https://orcid.org/0000-0002-3117-317X)
- Sandra De Meyer (ORCID: https://orcid.org/0000-0001-5524-7324)
- Natalia V. Voge (ORCID: https://orcid.org/0000-0002-4846-3325)
- Oliver Lenz
- Emérito Amaro-Carambot
- Xi Fang (ORCID: https://orcid.org/0000-0002-5212-6866)
- Stephen S. Whitehead (ORCID: https://orcid.org/0000-0001-6707-482X)
- Veerle Van Eygen (ORCID: https://orcid.org/0000-0001-8804-1613)
- Marnix Van Loock (ORCID: https://orcid.org/0000-0003-4151-4588)
- Nele Goeyvaerts (ORCID: https://orcid.org/0000-0003-0526-5318)
- Ruxandra Draghia‐Akli (ORCID: https://orcid.org/0000-0001-6372-4039)
- Freya Rasschaert (ORCID: https://orcid.org/0000-0003-1666-4533)
- Annemie Buelens (ORCID: https://orcid.org/0009-0002-0216-348X)
- Anna P. Durbin (ORCID: https://orcid.org/0000-0002-6652-2851)
- Thomas N. Kakuda (ORCID: https://orcid.org/0000-0001-6857-2572)
- Marya P. Carmolli
- Tine De Marez
- John E. Mayfield
- Haiyin He (ORCID: https://orcid.org/0009-0000-8957-9386)
- Kristen K. Pierce
- Kim De Clerck
- Isabel Fetter
- Laura Ebone
- Patricia Lutton
Institutions
- University of Vermont (US)
- Johnson & Johnson (United States) (US)
- Johns Hopkins University (US)
- National Institute of Allergy and Infectious Diseases (US)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1056/nejmoa2500179
- Citations
- 4
- Primary Topic
- Mosquito-borne diseases and control
- Type
- article
- Field-Weighted Citation Impact
- 7.51